JP2010535506A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010535506A5 JP2010535506A5 JP2010519988A JP2010519988A JP2010535506A5 JP 2010535506 A5 JP2010535506 A5 JP 2010535506A5 JP 2010519988 A JP2010519988 A JP 2010519988A JP 2010519988 A JP2010519988 A JP 2010519988A JP 2010535506 A5 JP2010535506 A5 JP 2010535506A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- affinity reagent
- cancer
- matriptase
- matriptase stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003153 chemical reaction reagent Substances 0.000 claims 14
- 108010091175 Matriptase Proteins 0.000 claims 12
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 239000003183 carcinogenic agent Substances 0.000 claims 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 231100000433 cytotoxic Toxicity 0.000 claims 3
- 230000001472 cytotoxic effect Effects 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 206010046766 uterine cancer Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000003197 catalytic effect Effects 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims 1
- 229940124651 anti-breast cancer agent Drugs 0.000 claims 1
- 229940124658 anti-colorectal cancer agent Drugs 0.000 claims 1
- 229930193936 anticarin Natural products 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000012642 immune effector Substances 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96383707P | 2007-08-07 | 2007-08-07 | |
| US60/963,837 | 2007-08-07 | ||
| PCT/US2008/009512 WO2009020645A2 (en) | 2007-08-07 | 2008-08-07 | Matriptase protein and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014155821A Division JP2014223083A (ja) | 2007-08-07 | 2014-07-31 | マトリプターゼタンパク質及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010535506A JP2010535506A (ja) | 2010-11-25 |
| JP2010535506A5 true JP2010535506A5 (enExample) | 2011-09-22 |
| JP5864856B2 JP5864856B2 (ja) | 2016-02-17 |
Family
ID=40239716
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010519988A Expired - Fee Related JP5864856B2 (ja) | 2007-08-07 | 2008-08-07 | マトリプターゼタンパク質及びその使用 |
| JP2014155821A Withdrawn JP2014223083A (ja) | 2007-08-07 | 2014-07-31 | マトリプターゼタンパク質及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014155821A Withdrawn JP2014223083A (ja) | 2007-08-07 | 2014-07-31 | マトリプターゼタンパク質及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8420091B2 (enExample) |
| EP (1) | EP2185933B1 (enExample) |
| JP (2) | JP5864856B2 (enExample) |
| AU (1) | AU2008284271B2 (enExample) |
| DK (1) | DK2185933T3 (enExample) |
| ES (1) | ES2550754T3 (enExample) |
| WO (1) | WO2009020645A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120294800A1 (en) * | 2009-01-07 | 2012-11-22 | University Of Medicine And Dentistry Of New Jersey | Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies |
| HUE034196T2 (en) * | 2009-03-05 | 2018-02-28 | Squibb & Sons Llc | Fully human antibodies specific for CADM1 |
| US9849192B2 (en) | 2009-11-18 | 2017-12-26 | Rutgers, The State University Of New Jersey | Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies |
| CA2818237C (en) | 2009-11-18 | 2021-05-18 | University Of Medicine And Dentistry Of New Jersey | Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies |
| EP2904015A4 (en) | 2012-10-02 | 2016-10-05 | Univ Rutgers | TARGETED RELEASE OF ANTIBODIES TO ACTIVATED MATRIPTASE-CONJUGATED TOXINS |
| BR112016011435A2 (pt) | 2013-11-25 | 2017-09-26 | Oxford Biotherapeutics Ltd | anticorpos anti-matriptase para o tratamento de câncer |
| EP3957994B1 (en) * | 2014-11-07 | 2025-02-19 | Fujikura Kasei Co., Ltd. | Digestive system cancer detection method using deoxyhypusine synthase gene as indicator |
| CN108778274A (zh) | 2016-03-18 | 2018-11-09 | 新泽西鲁特格斯州立大学 | 用通过可体内裂解的连接部分与抗蛋白裂解酶抗体缀合的化学治疗剂靶向肿瘤细胞 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5972616A (en) | 1998-02-20 | 1999-10-26 | The Board Of Trustees Of The University Of Arkansas | TADG-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas |
| US7022821B1 (en) | 1998-02-20 | 2006-04-04 | O'brien Timothy J | Antibody kit for the detection of TADG-15 protein |
| JP4778617B2 (ja) | 1999-03-12 | 2011-09-21 | ジョージタウン ユニバーシティ | マトリプターゼ、セリンプロテアーゼおよびその応用 |
| US7030231B1 (en) | 1999-09-30 | 2006-04-18 | Catalyst Biosciences, Inc. | Membrane type serine protease 1 (MT-SP1) and uses thereof |
| WO2001029056A1 (en) * | 1999-10-20 | 2001-04-26 | The Board Of Trustees Of The University Of Arkansas | Tadg-15: an extracellular serine protease overexpressed in carcinomas |
| US6447978B1 (en) | 1999-12-03 | 2002-09-10 | Kodak Polychrome Graphics Llc | Imaging member containing heat switchable polymer and method of use |
| IL150168A0 (en) | 2000-02-03 | 2002-12-01 | Corvas Int Inc | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods bsed thereon |
| US6903201B2 (en) | 2001-01-05 | 2005-06-07 | Curagen Corporation | Proteins and nucleic acids encoding same |
| WO2002072786A2 (en) | 2001-03-13 | 2002-09-19 | Corvas International, Inc. | Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon |
| CA2441378A1 (en) | 2001-03-22 | 2002-10-03 | Dendreon San Diego Llc | Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon |
| WO2002077267A2 (en) | 2001-03-27 | 2002-10-03 | Dendreon San Diego Llc | Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon |
| JP2005506832A (ja) | 2001-05-14 | 2005-03-10 | デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー | トランスメンブランセリンプロテアーゼ１０をコードする核酸分子、コードされるポリペプチドおよびそれに基づく方法 |
| US7019019B2 (en) | 2002-12-23 | 2006-03-28 | Dendreon Corporation | Matriptase inhibitors and methods of use |
| CN1985489B (zh) | 2004-07-09 | 2012-05-09 | 艾利森电话股份有限公司 | 在多媒体通信系统中提供不同服务的方法和装置 |
| US7572444B2 (en) | 2004-12-20 | 2009-08-11 | Amgen Fremont Inc. | Binding proteins specific for human matriptase |
| WO2006090389A2 (en) | 2005-02-24 | 2006-08-31 | Compugen Ltd. | Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof |
| EP1938104A2 (en) * | 2005-10-17 | 2008-07-02 | Institute for Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
-
2008
- 2008-08-07 EP EP08795130.7A patent/EP2185933B1/en not_active Not-in-force
- 2008-08-07 WO PCT/US2008/009512 patent/WO2009020645A2/en not_active Ceased
- 2008-08-07 AU AU2008284271A patent/AU2008284271B2/en not_active Ceased
- 2008-08-07 ES ES08795130.7T patent/ES2550754T3/es active Active
- 2008-08-07 JP JP2010519988A patent/JP5864856B2/ja not_active Expired - Fee Related
- 2008-08-07 DK DK08795130.7T patent/DK2185933T3/en active
-
2010
- 2010-02-07 US US12/701,566 patent/US8420091B2/en not_active Expired - Fee Related
-
2014
- 2014-07-31 JP JP2014155821A patent/JP2014223083A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010535506A5 (enExample) | ||
| JP2010518847A5 (enExample) | ||
| JP2009001563A5 (enExample) | ||
| JP2011509079A5 (enExample) | ||
| JP2008538289A5 (enExample) | ||
| Ayela et al. | Antibody–antigenic peptide interactions monitored by SPR and QCM-D: A model for SPR detection of IA-2 autoantibodies in human serum | |
| JP2015533788A5 (enExample) | ||
| CN106706914B (zh) | 用于诊断上皮源性癌症的血液标志物及单克隆抗体 | |
| JP2015516985A5 (enExample) | ||
| JP2019533807A5 (enExample) | ||
| JP2018042573A5 (enExample) | ||
| HRP20131047T1 (hr) | Identifikacija antigena povezanih s tumorom za dijagnozu i lijeäśenje | |
| JP2013520174A5 (enExample) | ||
| JP2015172045A5 (enExample) | ||
| CA2633171A1 (en) | Antibodies against tumor-associated antigenic target (tat) polypeptides | |
| JP2012515226A5 (enExample) | ||
| JP2015523852A5 (enExample) | ||
| US8105598B2 (en) | Human monoclonal antibodies that specifically bind IGF-II | |
| JP2016536330A5 (enExample) | ||
| HRP20192347T1 (hr) | Antitijela prema klaudinu 18.2 koja su korisna u dijagnozi tumora | |
| KR20190003959A (ko) | Dpp3을 결정하는 방법 및 치료 방법 | |
| EP2257572A1 (en) | Human anti-mesothelin monoclonal antibodies | |
| JP2014529297A (ja) | 新規な抗ｃｘｃｒ４抗体並びに癌の検出および診断のためのその使用 | |
| JP2014223083A5 (enExample) | ||
| JP2021073437A (ja) | 前立腺がんの分析のための組成物及び方法 |